Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Validity of Self-reported Diagnosis of Rheumatoid Arthritis.

Al Mutairi KB, Nossent JC, Inderjeeth CA.

J Rheumatol. 2020 Feb 15. pii: jrheum.191401. doi: 10.3899/jrheum.191401. [Epub ahead of print]

PMID:
32062603
2.

IL-1A gene variation in relation to cytokine levels and clinical characteristics in ankylosing spondylitis.

Nossent JC, Sagen-Johnsen S, Bakland G.

Eur J Rheumatol. 2018 Dec 18;6(2):67-70. doi: 10.5152/eurjrheum.2018.18150.

3.

The Impact of Cytokines on the Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus.

Raymond WD, Eilertsen GØ, Shanmugakumar S, Nossent JC.

J Clin Med. 2019 Jun 15;8(6). pii: E857. doi: 10.3390/jcm8060857.

4.

Infection Rates Before and After Diagnosis of IgA Vasculitis in Childhood: A Population-wide Study Using Non-exposed Matched Controls.

Nossent JC, Raymond W, Keen H, Preen DB, Inderjeeth CA.

J Rheumatol. 2019 Jun 15. pii: jrheum.190110. doi: 10.3899/jrheum.190110. [Epub ahead of print]

PMID:
31203216
5.

Disease Activity and Patient-Reported Health Measures in Relation to Cytokine Levels in Ankylosing Spondylitis.

Nossent JC, Sagen-Johnsen S, Bakland G.

Rheumatol Ther. 2019 Sep;6(3):369-378. doi: 10.1007/s40744-019-0161-7. Epub 2019 May 30.

6.

Sporadic late onset nemaline myopathy (SLONM) in an adult presenting with progressive muscle weakness.

Paramalingam S, Dyke JM, Nossent JC.

Eur J Rheumatol. 2018 Nov 6;6(2):105-107. doi: 10.5152/eurjrheum.2018.18071.

7.

IL23R gene variants in relation to IL17A levels and clinical phenotype in patients with ankylosing spondylitis.

Nossent JC, Sagen-Johnsen S, Bakland G.

Rheumatol Adv Pract. 2018 Feb 15;2(1):rky006. doi: 10.1093/rap/rky006. eCollection 2018.

8.

Recurrent podocytopathy in a patient with systemic lupus erythematosus.

Paramalingam S, Wong DD, Dogra GK, Nossent JC.

SAGE Open Med Case Rep. 2017 Feb 23;5:2050313X17695997. doi: 10.1177/2050313X17695997. eCollection 2017.

9.

Risk of mortality in patients with giant cell arteritis: A systematic review and meta-analysis.

Hill CL, Black RJ, Nossent JC, Ruediger C, Nguyen L, Ninan JV, Lester S.

Semin Arthritis Rheum. 2017 Feb;46(4):513-519. doi: 10.1016/j.semarthrit.2016.08.015. Epub 2016 Aug 25. Review.

PMID:
28040246
10.

The influence of ERAP1 gene variants on clinical phenotype in ankylosing spondylitis.

Nossent JC, Johnsen S, Bakland G.

Scand J Rheumatol. 2016 Nov;45(6):474-479. Epub 2016 Apr 20.

PMID:
27095091
11.

CD4 cell count and CD4/CD8 ratio increase during rituximab maintenance in granulomatosis with polyangiitis patients.

Besada E, Nossent JC.

PeerJ. 2016 Sep 20;4:e2487. doi: 10.7717/peerj.2487. eCollection 2016.

12.

Increased von Willebrand factor levels in patients with systemic lupus erythematosus reflect inflammation rather than increased propensity for platelet activation.

Nossent JC, Raymond WD, Eilertsen GØ.

Lupus Sci Med. 2016 Aug 15;3(1):e000162. doi: 10.1136/lupus-2016-000162. eCollection 2016.

13.

Hoffa-Synovitis and Pain Sensitization: Comment on the Article by Neogi et al.

Nossent JC.

Arthritis Rheumatol. 2016 Jul;68(7):1791. doi: 10.1002/art.39696. No abstract available.

14.

Staphylococcus Aureus carriage and long-term Rituximab treatment for Granulomatosis with polyangiitis.

Besada E, Koldingsnes W, Nossent JC.

PeerJ. 2015 Jun 25;3:e1051. doi: 10.7717/peerj.1051. eCollection 2015.

15.

Not only monoclonal antibodies...

Nossent JC.

Intern Med J. 2015 May;45(5):590. doi: 10.1111/imj.12742. No abstract available.

PMID:
25955470
16.

A remarkably useless new name in rheumatology.

Nossent JC.

Arthritis Rheumatol. 2015 Jun;67(6):1685. doi: 10.1002/art.39103. No abstract available.

17.

Clinical phenotype associations with various types of anti-dsDNA antibodies in patients with recent onset of rheumatic symptoms. Results from a multicentre observational study.

Compagno M, Rekvig OP, Bengtsson AA, Sturfelt G, Heegaard NH, Jönsen A, Jacobsen RS, Eilertsen GØ, Fenton CG, Truedsson L, Nossent JC, Jacobsen S.

Lupus Sci Med. 2014 Apr 1;1(1):e000007. doi: 10.1136/lupus-2013-000007. eCollection 2014.

18.

APRIL levels strongly correlate with IL-17 in systemic lupus erythematosus.

Eilertsen GØ, Nossent JC.

Lupus. 2014 Nov;23(13):1383-91. doi: 10.1177/0961203314543914. Epub 2014 Jul 23.

PMID:
25057039
19.
20.

Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis.

Besada E, Koldingsnes W, Nossent JC.

Rheumatology (Oxford). 2014 Oct;53(10):1818-24. doi: 10.1093/rheumatology/keu194. Epub 2014 May 15.

PMID:
24831059
21.

The distribution of HLA-B27 subtype in patients with ankylosing spondylitis in Northern Norway.

Johnsen SS, Bakland G, Nossent JC.

Scand J Rheumatol. 2014;43(4):296-300. doi: 10.3109/03009742.2013.863381. Epub 2014 Feb 11.

PMID:
24517504
22.

Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre.

Besada E, Koldingsnes W, Nossent JC.

Rheumatology (Oxford). 2013 Nov;52(11):2041-7. doi: 10.1093/rheumatology/ket257. Epub 2013 Aug 11.

PMID:
23934313
23.

Susceptibility for Lupus Nephritis by Low Copy Number of the FCGR3B Gene Is Linked to Increased Levels of Pathogenic Autoantibodies.

Nossent JC, Becker-Merok A, Rischmueller M, Lester S.

Autoimmune Dis. 2013;2013:750814. doi: 10.1155/2013/750814. Epub 2013 Jun 20.

24.

Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?

Besada E, Nossent JC.

Clin Rheumatol. 2013 Nov;32(11):1677-81. doi: 10.1007/s10067-013-2293-4. Epub 2013 Jun 11.

PMID:
23754241
25.

Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review.

Besada E, Vik A, Koldingsnes W, Nossent JC.

Int J Hematol. 2013 Jun;97(6):800-3. doi: 10.1007/s12185-013-1323-y. Epub 2013 Apr 25. Review.

PMID:
23616220
26.

Infection risks during longterm rituximab therapy change over time.

Besada E, Nossent JC.

J Rheumatol. 2013 Feb;40(2):203. doi: 10.3899/jrheum.121247. No abstract available.

PMID:
23378496
27.

Circulating interferon-α2 levels are increased in the majority of patients with systemic lupus erythematosus and are associated with disease activity and multiple cytokine activation.

Becker-Merok A, Østli-Eilersten G, Lester S, Nossent J.

Lupus. 2013 Feb;22(2):155-63. doi: 10.1177/0961203312468964. Epub 2012 Dec 4.

PMID:
23213068
28.

Low copy number of the Fc-γ receptor 3B gene FCGR3B is a risk factor for primary Sjogren's syndrome.

Nossent JC, Rischmueller M, Lester S.

J Rheumatol. 2012 Nov;39(11):2142-7. doi: 10.3899/jrheum.120294. Epub 2012 Sep 1.

PMID:
22942264
29.

Imported case of visceral leishmaniasis presenting as pancytopenia in a Norwegian patient treated with methotrexate and etanercept for psoriasis arthritis.

Besada E, Njålla RJ, Nossent JC.

Rheumatol Int. 2013 Oct;33(10):2687-9. doi: 10.1007/s00296-012-2483-4. Epub 2012 Aug 12.

PMID:
22886470
30.

Assessment of SpondyloArthritis International Society criteria for axial spondyloarthritis in chronic back pain patients with a high prevalence of HLA-B27.

Bakland G, Alsing R, Singh K, Nossent JC.

Arthritis Care Res (Hoboken). 2013 Mar;65(3):448-53. doi: 10.1002/acr.21804.

31.

Ultrasonographic resolution of the vessel wall oedema with modest clinical improvement in a large-vessel vasculitis patient treated with tocilizumab.

Besada E, Nossent JC.

Clin Rheumatol. 2012 Aug;31(8):1263-5. doi: 10.1007/s10067-012-2007-3. Epub 2012 Jun 2. Review.

PMID:
22661052
32.

Low copy number of the FCGR3B gene and rheumatoid arthritis: a case-control study and meta-analysis.

Graf SW, Lester S, Nossent JC, Hill CL, Proudman SM, Lee A, Rischmueller M.

Arthritis Res Ther. 2012 Feb 7;14(1):R28. doi: 10.1186/ar3731.

33.

[New criteria for rheumatoid arthritis].

Nikolaisen C, Besada E, Nossent JC.

Tidsskr Nor Laegeforen. 2012 Jan 24;132(2):175-7. doi: 10.4045/tidsskr.11.0604. Norwegian. No abstract available.

34.

Increased levels of BAFF in patients with systemic lupus erythematosus are associated with acute-phase reactants, independent of BAFF genetics: a case-control study.

Eilertsen GØ, Van Ghelue M, Strand H, Nossent JC.

Rheumatology (Oxford). 2011 Dec;50(12):2197-205. doi: 10.1093/rheumatology/ker282. Epub 2011 Oct 8.

PMID:
21984763
35.

Increased mortality in ankylosing spondylitis is related to disease activity.

Bakland G, Gran JT, Nossent JC.

Ann Rheum Dis. 2011 Nov;70(11):1921-5. doi: 10.1136/ard.2011.151191. Epub 2011 Jul 21.

PMID:
21784726
36.

Interleukin-6 promotes arthritis and joint deformation in patients with systemic lupus erythematosus.

Eilertsen GØ, Nikolaisen C, Becker-Merok A, Nossent JC.

Lupus. 2011 May;20(6):607-13. doi: 10.1177/0961203310392432. Epub 2011 Mar 21.

PMID:
21422077
37.

Work disability in patients with ankylosing spondylitis in Norway.

Bakland G, Gran JT, Becker-Merok A, Nordvåg BY, Nossent JC.

J Rheumatol. 2011 Mar;38(3):479-84. doi: 10.3899/jrheum.100686. Epub 2011 Feb 1.

PMID:
21285159
38.

Rituximab or cyclophosphamide in ANCA-associated renal vasculitis.

Nossent JC.

N Engl J Med. 2010 Nov 18;363(21):2072; author reply 2073-4. doi: 10.1056/NEJMc1009101. No abstract available.

PMID:
21083400
39.

Levels of transforming growth factor-beta are low in systemic lupus erythematosus patients with active disease.

Becker-Merok A, Eilertsen GØ, Nossent JC.

J Rheumatol. 2010 Oct;37(10):2039-45. doi: 10.3899/jrheum.100180. Epub 2010 Aug 3.

PMID:
20682675
40.

Decreased incidence of lupus nephritis in northern Norway is linked to increased use of antihypertensive and anticoagulant therapy.

Eilertsen GØ, Fismen S, Hanssen TA, Nossent JC.

Nephrol Dial Transplant. 2011 Feb;26(2):620-7. doi: 10.1093/ndt/gfq435. Epub 2010 Jul 19.

PMID:
20647194
41.

[When the obvious is not the common].

Nossent JC.

Tidsskr Nor Laegeforen. 2009 Nov 19;129(22):2372. doi: 10.4045/tidsskr.09.0969. Norwegian. No abstract available.

42.

Prevalence, predictors and outcome of vascular damage in systemic lupus erythematosus.

Becker-Merok A, Nossent J.

Lupus. 2009 May;18(6):508-15. doi: 10.1177/0961203308099233.

PMID:
19395452
43.

Epidemiological and clinical characteristics of psoriatic arthritis in northern Norway.

Nossent JC, Gran JT.

Scand J Rheumatol. 2009;38(4):251-5. doi: 10.1080/03009740802609558.

PMID:
19247847
44.

Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.

Nikolaisen C, Kvien TK, Mikkelsen K, Kaufmann C, Rødevand E, Nossent JC.

Scand J Rheumatol. 2009;38(4):240-5. doi: 10.1080/03009740802609566.

PMID:
19229766
45.

The influence of the 1997 updated classification criteria for systemic lupus erythematosus: epidemiology, disease presentation, and patient management.

Eilertsen GØ, Becker-Merok A, Nossent JC.

J Rheumatol. 2009 Mar;36(3):552-9. doi: 10.3899/jrheum.080574. Epub 2009 Jan 22.

PMID:
19208593
46.

Polymorphism in the 5' regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjogren's syndrome.

Nossent JC, Lester S, Zahra D, Mackay CR, Rischmueller M.

Rheumatology (Oxford). 2008 Sep;47(9):1311-6. doi: 10.1093/rheumatology/ken246. Epub 2008 Jul 10.

PMID:
18617551
47.
48.

Erythroleukaemia complicating ANA-negative systemic lupus erythematosus.

Eilertsen GØ, Nossent JC.

Scand J Rheumatol. 2007 Nov-Dec;36(6):478-80. No abstract available.

PMID:
18092272
49.

Increased ferritin response in adult Still's disease: specificity and relationship to outcome.

Evensen KJ, Swaak TJ, Nossent JC.

Scand J Rheumatol. 2007 Mar-Apr;36(2):107-10.

PMID:
17476616
50.

Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis.

Becker-Merok A, Kalaaji M, Haugbro K, Nikolaisen C, Nilsen K, Rekvig OP, Nossent JC.

Arthritis Res Ther. 2006;8(6):R162.

Supplemental Content

Loading ...
Support Center